We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Lowering Cholesteryl Ester Levels Reduces Tau Tangles

By LabMedica International staff writers
Posted on 07 Feb 2019
An excess of cholesteryl esters, the storage product for excess cholesterol within cells, was shown to induce tau protein in neurons to form abnormal aggregates called neurofibrillary tangles that are characteristic of Alzheimer's disease.

Previous studies have determined that predisposition to Alzheimer’s disease (AD) may arise from altered cholesterol metabolism, although the molecular pathways that may link cholesterol to AD phenotypes are only partially understood.

In this regard, investigators at the University of California, San Diego (USA) performed a phenotypic screen for phosphorylated tau (pTau) accumulation in AD-patient iPSC (induced pluripotent stem cell)-derived neurons, which carried mutations in the cholesterol-binding domain of (Amyloid precursor protein) APP or lacked APP altogether.

The investigators reported in the January 24, 2019, online edition of the journal Cell Stem Cell that they had identified cholesteryl esters as upstream regulators of tau during early AD development. More...
They also found that while cholesteryl esters regulated Abeta secretion, their effects on tau and Abeta were mediated by independent pathways.

Efficacy and toxicity screening in iPSC-derived astrocytes and neurons showed that allosteric activation of the neuronal enzyme CYP46A1 lowered cholesteryl ester levels specifically in neurons and was well tolerated by astrocytes. Thus, cholesteryl esters were found to independently regulate tau and Abeta and could be reduced by a drug such as the anti-HIV drug efavirenz, which activates CYP46A1 and thereby reduces tau in AD-patient neurons.

“Our findings reveal that cholesteryl esters act on tau, which means more options and new possibilities for therapeutic intervention,” said senior author Dr. Lawrence S.B. Goldstein, professor of cellular and molecular medicine at the University of California, San Diego. “Identification of the CYP46A1-cholesteryl ester-tau axis means we have a druggable target and a potential therapeutic pathway in early AD.”

Related Links:
University of California, San Diego


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Serological Pipet Controller
PIPETBOY GENIUS
New
Pan-Cancer Panel
TruSight Oncology 500
New
Specimen Radiography System
TrueView 200 Pro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.